PE20211709A1 - Anticuerpos que reconocen tau - Google Patents
Anticuerpos que reconocen tauInfo
- Publication number
- PE20211709A1 PE20211709A1 PE2021001286A PE2021001286A PE20211709A1 PE 20211709 A1 PE20211709 A1 PE 20211709A1 PE 2021001286 A PE2021001286 A PE 2021001286A PE 2021001286 A PE2021001286 A PE 2021001286A PE 20211709 A1 PE20211709 A1 PE 20211709A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- chain cdrs
- antibodies
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803334P | 2019-02-08 | 2019-02-08 | |
| US201962813124P | 2019-03-03 | 2019-03-03 | |
| US201962855434P | 2019-05-31 | 2019-05-31 | |
| PCT/US2020/017357 WO2020163817A1 (en) | 2019-02-08 | 2020-02-07 | Antibodies recognizing tau |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211709A1 true PE20211709A1 (es) | 2021-09-01 |
Family
ID=71947192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001286A PE20211709A1 (es) | 2019-02-08 | 2020-02-07 | Anticuerpos que reconocen tau |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220275067A1 (enExample) |
| EP (1) | EP3921343A4 (enExample) |
| JP (2) | JP7681316B2 (enExample) |
| KR (1) | KR20210125037A (enExample) |
| CN (2) | CN113597431B (enExample) |
| AU (1) | AU2020219374B2 (enExample) |
| BR (1) | BR112021015501A2 (enExample) |
| CA (1) | CA3128392A1 (enExample) |
| CO (1) | CO2021011140A2 (enExample) |
| IL (1) | IL285444A (enExample) |
| MX (1) | MX2021009440A (enExample) |
| PE (1) | PE20211709A1 (enExample) |
| SG (1) | SG11202106717PA (enExample) |
| WO (1) | WO2020163817A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| US10906964B2 (en) | 2016-05-02 | 2021-02-02 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| MX2018013384A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| SG11202106717PA (en) * | 2019-02-08 | 2021-07-29 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| TWI859197B (zh) | 2019-03-03 | 2024-10-21 | 愛爾蘭商普羅帝納生物科學公司 | 識別ｔａｕ之抗體 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| CA3226301A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| CN117003872A (zh) * | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 含有突变轻链可变区骨架的单链抗体片段 |
| JP2023175325A (ja) * | 2022-05-30 | 2023-12-12 | 学校法人順天堂 | タウオパチーの鑑別診断法 |
| WO2025198916A1 (en) * | 2024-03-16 | 2025-09-25 | Abbvie Inc. | Anti-tau antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001018546A2 (en) * | 1999-09-09 | 2001-03-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening for inhibitors of 'paired helical filaments' |
| US8754034B2 (en) * | 2009-02-06 | 2014-06-17 | The Regents Of The University Of California | Structure-based design of peptide inhibitors of amyloid fibrillation |
| CN102596236B (zh) * | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
| WO2012106363A2 (en) * | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| GB201111361D0 (en) | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
| EP3275461A1 (en) | 2011-09-19 | 2018-01-31 | Axon Neuroscience SE | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field |
| WO2013059786A1 (en) * | 2011-10-21 | 2013-04-25 | The Ohio State University | Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease |
| US9200068B2 (en) * | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| WO2014165271A2 (en) * | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| US20150253341A1 (en) * | 2014-02-10 | 2015-09-10 | Merck Sharp & Dohme Corp. | Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry |
| NZ775762A (en) * | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| JP7725185B2 (ja) * | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| US11319372B2 (en) * | 2017-02-21 | 2022-05-03 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4) |
| SG11202106717PA (en) * | 2019-02-08 | 2021-07-29 | Prothena Biosciences Ltd | Antibodies recognizing tau |
-
2020
- 2020-02-07 SG SG11202106717PA patent/SG11202106717PA/en unknown
- 2020-02-07 EP EP20753068.4A patent/EP3921343A4/en active Pending
- 2020-02-07 AU AU2020219374A patent/AU2020219374B2/en active Active
- 2020-02-07 PE PE2021001286A patent/PE20211709A1/es unknown
- 2020-02-07 JP JP2021569259A patent/JP7681316B2/ja active Active
- 2020-02-07 WO PCT/US2020/017357 patent/WO2020163817A1/en not_active Ceased
- 2020-02-07 BR BR112021015501-5A patent/BR112021015501A2/pt unknown
- 2020-02-07 CA CA3128392A patent/CA3128392A1/en active Pending
- 2020-02-07 KR KR1020217028112A patent/KR20210125037A/ko active Pending
- 2020-02-07 MX MX2021009440A patent/MX2021009440A/es unknown
- 2020-02-07 US US17/429,288 patent/US20220275067A1/en active Pending
- 2020-02-07 CN CN202080018281.7A patent/CN113597431B/zh active Active
- 2020-02-07 CN CN202510128272.8A patent/CN119954947A/zh active Pending
-
2021
- 2021-08-08 IL IL285444A patent/IL285444A/en unknown
- 2021-08-24 CO CONC2021/0011140A patent/CO2021011140A2/es unknown
-
2024
- 2024-11-29 JP JP2024209068A patent/JP7843068B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021011140A2 (es) | 2021-09-20 |
| BR112021015501A2 (pt) | 2021-10-19 |
| MX2021009440A (es) | 2021-09-10 |
| JP7843068B2 (ja) | 2026-04-09 |
| EP3921343A4 (en) | 2022-12-14 |
| CN113597431B (zh) | 2025-02-21 |
| KR20210125037A (ko) | 2021-10-15 |
| EP3921343A1 (en) | 2021-12-15 |
| CA3128392A1 (en) | 2020-08-13 |
| WO2020163817A1 (en) | 2020-08-13 |
| IL285444A (en) | 2021-09-30 |
| CN113597431A (zh) | 2021-11-02 |
| JP2022520672A (ja) | 2022-03-31 |
| AU2020219374A1 (en) | 2021-07-01 |
| CN119954947A (zh) | 2025-05-09 |
| US20220275067A1 (en) | 2022-09-01 |
| JP2025029046A (ja) | 2025-03-05 |
| SG11202106717PA (en) | 2021-07-29 |
| JP7681316B2 (ja) | 2025-05-22 |
| AU2020219374B2 (en) | 2026-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20210073A7 (es) | Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs | |
| CL2024003412A1 (es) | Anticuerpos anti-tl1a y métodos de uso de los mismos | |
| ES2523740T3 (es) | Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 | |
| PE20221511A1 (es) | Anticuerpos anti-ly6g6d y metodos de uso | |
| CY1123212T1 (el) | Συνθεσεις για την αναστολη της ενεργοποιησης του masp-2 εξαρτωμενου συμπληρωματος | |
| PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| PE20190212A1 (es) | Anticuerpos anti_ige | |
| PE20220279A1 (es) | Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| PE20191546A1 (es) | Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb | |
| PE20251639A1 (es) | Anticuerpos que se unen a interleuquina 13 y metodos de uso | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
| MX338694B (es) | Composiciones y metodos para el diagnostico y el tratamiento de tumores. | |
| PE20191075A1 (es) | Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo | |
| AR115192A1 (es) | Anticuerpos | |
| JP2013091655A5 (enExample) | ||
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| PE20191076A1 (es) | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo | |
| CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu | |
| AR078796A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| CO6180454A2 (es) | Anticuerpos de la egfl7 y metodos de uso | |
| PE20231680A1 (es) | Anticuerpos anti-cd30l y usos de estos |